**Endemicity status:**
- Endemic
- Non endemic

**Number of new cases (incidence):**
- 8,500
- No data
- 648
- N/A

**Number of relapse cases:**
- 1
- No data
- No data
- N/A

**Total number of cases:**
- 8,500
- No data
- 648
- N/A

**Imported cases (number, %):**
- 0, 0%
- No data
- N/A
- N/A

**Gender distribution (% F):**
- 39
- No data
- N/A
- N/A

**Age group distribution (% < 5/5-14/>14):**
- 4/27/53
- No data
- 1/20/76
- N/A

**Incidence rate (cases/10,000 population in endemic areas):**
- 0.62
- No data
- N/A
- N/A

**Number of endemic 3rd sub-national administrative level divisions:**
- 603
- No data
- N/A
- N/A

**Population at risk (%) # at risk/total population:**
- 10%
- 136,482,825/1,300,000,000
- N/A
- N/A

**Was there any outbreak?**
- Yes
- Unknown

**Number of new foci:**
- No data
- No data
- N/A
- N/A

---

**COUNTRY GENERAL INFORMATION (WHO, 2015)**

- **Total population:** 1,300,000,000
- **Gender F/M (%):** 48.5 / 51.5
- **Population, age group <15/>15 years (%):** 29 / 71
- **Life expectancy at birth (F/M, years) (2015):** 70 / 67
- **GDP (PPP int $):** 6,050
- **Income status:** Lower middle

---

**EPIDEMIOLOGY**

<table>
<thead>
<tr>
<th></th>
<th>VL</th>
<th>CL</th>
<th>PKDL</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endemicity status</td>
<td>Endemic</td>
<td>Endemic</td>
<td>Endemic</td>
<td>Non endemic</td>
</tr>
<tr>
<td>Number of new cases</td>
<td>8,500</td>
<td>No data</td>
<td>648</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of relapse</td>
<td>No data</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Total number of cases</td>
<td>8,500</td>
<td>No data</td>
<td>648</td>
<td>N/A</td>
</tr>
<tr>
<td>Imported cases</td>
<td>No data</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Gender distribution</td>
<td>39</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Age group distribution</td>
<td>[4/27/53]</td>
<td>No data</td>
<td>[1/20/76]</td>
<td>N/A</td>
</tr>
<tr>
<td>Incidence rate</td>
<td>0.62</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of endemic 3rd sub-national administrative level divisions</td>
<td>603</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Population at risk</td>
<td>10%</td>
<td>136,482,825/1,300,000,000</td>
<td>No data</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Was there any outbreak?**
- Yes
- Unknown

**Number of new foci:**
- No data
- No data
- N/A
- N/A

---

**Monthly distribution of new cases (January-December)**

<table>
<thead>
<tr>
<th>Year</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>496</td>
<td>806</td>
<td>861</td>
<td>887</td>
<td>827</td>
<td>806</td>
<td>754</td>
<td>633</td>
<td>902</td>
<td>519</td>
<td>417</td>
<td>554</td>
</tr>
</tbody>
</table>

**Visceral leishmaniasis**

- Number of new VL cases 2015
- Number of new VL cases 2014

**Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015**

**Visceral leishmaniasis**

- Number of VL cases
- Incidence rate (1/10,000)

**Cutaneous leishmaniasis**

- Number of CL cases
- Incidence rate (1/10,000)
CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established: 1992
Type of surveillance: Vertical
Is there a vector control programme?: Yes
Type of insecticide used for Indoor residual Spraying (IRS): DDT, Synthetic Pyrethroids
Year latest national guidelines: 2015
Is leishmaniasis notifiable (mandatory report)? Yes
Is there a reservoir host control programme?: Yes
Number of leishmaniasis health facilities: 611

DIAGNOSIS

Number of people screened actively for:
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Number of people screened passively for:
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Cases diagnosed by RDT* (%: # RDT+/ total VL cases):
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Proportion of positive RDT* (%: # RDT+/total RDT):
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Cases diagnosed by direct exam* (parasitology) (%: # slides + / total cases):
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Proportion of positive slides* (%: # slides + / total slides):
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Cases diagnosed clinically* (%: # clinical cases/ total cases):
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:
- VL: No data
- CL: No data
- PKDL: N/A
- MCL: N/A
Proportion of CL cases with 4 or more lesions* (%: # CL cases/ total CL cases):
- VL: N/A
- CL: No data
- PKDL: N/A
- MCL: N/A
Percentage of cases with HIV coinfection*:
- VL: 1% (45/8,500)
- CL: N/A
- PKDL: 0% (0/648)
- MCL: N/A

TREATMENT AND MEDICINES

Is treatment provided for free in the public sector?: Yes
Antileishmanial medicines included in the National Medicine List: Liposomal Amphotericin B, Sodium stibogluconate (SSG), Amphotericin B deoxycholate, Miltefosine

TREATMENT OUTCOME

Proportion of cases treated* (%: # treated cases/ total cases):
- VL: 94% (7,967/8,500)
- CL: No data
Initial cure rate* (%: # cases initially cured /total cases):
- VL: No data
- CL: No data
Failure rate* (%: # patients with treatment failure /total cases):
- VL: No data
- CL: No data
Case fatality rate* (%: # patients who died/ total cases):
- VL: 0.06% (5/8,500)
- CL: No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis
* Failure in this country is defined as: No definition available.
* These indicators only apply to new cases.